Skip to main content
. Author manuscript; available in PMC: 2009 Aug 12.
Published in final edited form as: Vaccine. 2008 Jun 23;26(34):4338–4344. doi: 10.1016/j.vaccine.2008.06.010

Figure 3.

Figure 3

Kinetics of the prevalence of IFN-γ secreting cells determined by ELISPOT in PBMC obtained from animals immunized with different formulations of rPvRII after ex vivo stimulation with the recombinant protein. Data are presented for individual animal at different time points and expressed as IFN-γ spot forming cells per 1×106 PBMC. Average values for medium control wells in the presence of cytokines were initially subtracted from the average values obtained from antigen-stimulated wells. To take in consideration individual variability, recall PvRII-reactive T cells were calculated by subtracting the spot forming cells obtained with pre-immune samples. Rhesus macaques were immunized with 50 μg P. vivax DBP RII (closed symbols) or 10 μg P. vivax DBP RII (open symbols) formulated with Alhydrogel (A), Montanide ISA 720 (B) or AS02A (C).